Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NOVAVAX INCNVAX · Entity 4632 | EVP, Research & Development | March 02, 2026 | March 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NOVAVAX INC
Report date March 02, 2026 · Filed March 09, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Statutory Stock Option NQSEC Table II · derivative / convertible security · Conversion / exercise price $10.11 · Expires 2036-03-02 | Direct | 139,500 |
Reported balance
After 2026-03-02 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-03-02 · Grant · Acquired 139,500 · Balance 139,500 F1: This Form 4/A has been filed solely to amend the exercise price as originally reported in Column 2 and price of derivative security as originally reported in Column 8 of Table II of the Reporting Person's Form 4 filed on March 5, 2026. All other information remains unchanged from the March 5, 2026 filing. F2: One quarter (1/4) of the shares subject to this option granted under the Plan vest on the first anniversary of March 2, 2026, and the remaining three-quarters (3/4) of the shares vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4/A has been filed solely to amend the exercise price as originally reported in Column 2 and price of derivative security as originally reported in Column 8 of Table II of the Reporting Person's Form 4 filed on March 5, 2026. All other information remains unchanged from the March 5, 2026 filing.
F2: One quarter (1/4) of the shares subject to this option granted under the Plan vest on the first anniversary of March 2, 2026, and the remaining three-quarters (3/4) of the shares vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 03, 2026 Filed Mar 5, 2026 11:00 UTC | NOVAVAX INC NVAX · Entity 4632 | Disposition to issuerRestricted Stock Units · Derivative | 26,667 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-023709 · tm268076-5_4seq1.xml · derivative · entry 5 Draghia-Akli Ruxandra · CIK 0002041719 · EVP, Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,333 Underlying: Common Stock · 26,667 shares Expires 2035-03-03 F4 · derivative.exercise_date: One-third (1/3) of the RSUs subject to this grant under the Plan vest on each of the first three (3) anniversaries of March 3, 2025, in each case subject to continued employment through such vesting date. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 11:00 UTC | NOVAVAX INC NVAX · Entity 4632 | Tax withholdingCommon Stock | 11,313 | $9.49 | $107,360.37 |
DisclosureSEC source: 0001104659-26-023709 · tm268076-5_4seq1.xml · nonDerivative · entry 2 Draghia-Akli Ruxandra · CIK 0002041719 · EVP, Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,563 F1 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 11:00 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 26,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-023709 · tm268076-5_4seq1.xml · nonDerivative · entry 1 Draghia-Akli Ruxandra · CIK 0002041719 · EVP, Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,876 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 11:00 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantNon-Statutory Stock Opotion NQ · Derivative | 139,500 | $9.09 Strike: $9.09 | $1,268,055.00 |
DisclosureSEC source: 0001104659-26-023709 · tm268076-5_4seq1.xml · derivative · entry 4 Draghia-Akli Ruxandra · CIK 0002041719 · EVP, Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,500 Underlying: Common Stock · 139,500 shares Expires 2036-03-02 F3 · derivative.exercise_date: One quarter of the shares subject to this option granted under the Plan vest on the first anniversary of March 2, 2026, and the remaining three-quarters (3/4) of the shares vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 11:00 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantRestricted Stock Units · Derivative | 93,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-023709 · tm268076-5_4seq1.xml · derivative · entry 3 Draghia-Akli Ruxandra · CIK 0002041719 · EVP, Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,000 Underlying: Common Stock · 93,000 shares Expires 2036-03-02 F2 · derivative.exercise_date: One-third (1/3) of the RSUs subject to this grant under Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended, (the "Plan") vest on each of the first three (3) anniversaries of March 2, 2026, in each case subject to continued employment through such vesting date. Read SEC document |
| March 02, 2026 Filed Mar 9, 2026 22:11 UTC Amendment | NOVAVAX INC NVAX · Entity 4632 | GrantNon-Statutory Stock Option NQ · Derivative | 139,500 | $0.00 Strike: $10.11 | $0.00 |
DisclosureSEC source: 0001104659-26-025366 · tm268290-4_4aseq1.xml · derivative · entry 1 Draghia-Akli Ruxandra · CIK 0002041719 · EVP, Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,500 Underlying: Common Stock · 139,500 shares Expires 2036-03-02 F1 · derivative.exercise_price: This Form 4/A has been filed solely to amend the exercise price as originally reported in Column 2 and price of derivative security as originally reported in Column 8 of Table II of the Reporting Person's Form 4 filed on March 5, 2026. All other information remains unchanged from the March 5, 2026 filing. F1 · price: This Form 4/A has been filed solely to amend the exercise price as originally reported in Column 2 and price of derivative security as originally reported in Column 8 of Table II of the Reporting Person's Form 4 filed on March 5, 2026. All other information remains unchanged from the March 5, 2026 filing. F2 · derivative.exercise_date: One quarter (1/4) of the shares subject to this option granted under the Plan vest on the first anniversary of March 2, 2026, and the remaining three-quarters (3/4) of the shares vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 22:23 UTC | NOVAVAX INC NVAX · Entity 4632 | Disposition to issuerRestricted Stock Units · Derivative | 14,257 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-111494 · tm2531249-1_4seq1.xml · derivative · entry 3 Draghia-Akli Ruxandra · CIK 0002041719 · Section 16 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,513 Underlying: Common Stock · 14,257 shares Expires 2034-11-11 F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Company common stock. F2 · derivative.exercise_date: One-third (1/3) of the RSUs subject to this grant under the Plan vest on each of the first three (3) anniversaries of the grant date, in each case subject to continued employment through such vesting date. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 22:23 UTC | NOVAVAX INC NVAX · Entity 4632 | Tax withholdingCommon Stock | 6,048 | $7.40 | $44,755.20 |
DisclosureSEC source: 0001104659-25-111494 · tm2531249-1_4seq1.xml · nonDerivative · entry 2 Draghia-Akli Ruxandra · CIK 0002041719 · Section 16 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,209 Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 22:23 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 14,257 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-111494 · tm2531249-1_4seq1.xml · nonDerivative · entry 1 Draghia-Akli Ruxandra · CIK 0002041719 · Section 16 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,257 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 22:04 UTC | NOVAVAX INC NVAX · Entity 4632 | Grant2025 Restricted Stock Units RSU · Derivative | 80,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001593968-25-000305 · primary_01.xml · derivative · entry 2 Draghia-Akli Ruxandra · CIK 0002041719 · Section 16 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2035-03-03 F2 · derivative.exercise_date: One-third (1/3) of the RSUs subject to this grant under the Plan vest on each of the first three (3) anniversaries of the grant date, in each case subject to continued employment through such vesting date. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 22:04 UTC | NOVAVAX INC NVAX · Entity 4632 | Grant2025 Non-statutory Stock Option NQ · Derivative | 120,000 | $7.87 Strike: $7.87 | $944,400.00 |
DisclosureSEC source: 0001593968-25-000305 · primary_01.xml · derivative · entry 1 Draghia-Akli Ruxandra · CIK 0002041719 · Section 16 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2035-03-03 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option granted under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended, vest on the first anniversary of the grant date, and the remaining seventy-five percent (75%) of the shares vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date. Read SEC document |
| November 11, 2024 Filed Nov 13, 2024 21:08 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantRestricted Stock Units · Derivative | 42,770 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-24-001367 · primary_01.xml · derivative · entry 2 Draghia-Akli Ruxandra · CIK 0002041719 · Section 16 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,770 Underlying: Common Stock · 42,770 shares Expires 2034-11-11 F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Company common stock. F3 · derivative.exercise_date: One-third (1/3) of the RSUs subject to this grant under the Plan vest on each of the first three (3) anniversaries of the grant date, in each case subject to continued employment through such vesting date. Read SEC document |
| November 11, 2024 Filed Nov 13, 2024 21:08 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantStock Option (Right to Buy) · Derivative | 64,150 | $9.01 Strike: $9.01 | $577,991.50 |
DisclosureSEC source: 0001593968-24-001367 · primary_01.xml · derivative · entry 1 Draghia-Akli Ruxandra · CIK 0002041719 · Section 16 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,150 Underlying: Common Stock · 64,150 shares Expires 2034-11-11 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option granted under the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended, vest on the first anniversary of the grant date, and the remaining seventy-five percent (75%) of the shares vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.